Skip to main content


Fig. 2 | EJNMMI Research

Fig. 2

From: A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions

Fig. 2

Changing patterns of PET parameters in the responder group. a, b Isocontour and SUVmean show increasing pattern in malignant lesions after the use of pioglitazone. c, d In hepatobiliary cancer, 12 out of the 18 lesions show increasing patterns of SUVmean. Four out of the 12 increase more than 1 SD. e In gastrointestinal cancer, 14 out of the 15 lesions have increasing patterns of isocontour. Six out of the 14 lesions show significant increase more than 1 standard deviation (SD). f On the other hand, in inflammatory lesions, there is no statistically significant increase

Back to article page